Back to Journals » Neuropsychiatric Disease and Treatment » Volume 10

Long-term efficacy and safety of iloperidone: an update

Authors Rado J, Janicak P

Received 16 August 2013

Accepted for publication 5 November 2013

Published 26 February 2014 Volume 2014:10 Pages 409—415


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Jeffrey T Rado, Philip G Janicak

Rush University Medical Center, Chicago, IL, USA

Abstract: Schizophrenia is a devastating neuropsychiatric disease with a worldwide prevalence of approximately 0.5%–1%. Since many patients do not achieve adequate symptom relief from available agents, alternate pharmacotherapeutic approaches are needed. In this context, iloperidone was recently approved by the US Food and Drug Administration for the treatment of schizophrenia. This paper first reviews its pharmacodynamic and pharmacokinetic profiles, emphasizing their clinical relevance. Next, it summarizes the literature on its acute and maintenance efficacy, safety, and tolerability. It then considers pharmacogenetic data which may help to predict response and risk of cardiac arrhythmias with this agent. Finally, it critically positions iloperidone relative to other first- and second-generation antipsychotics.

Keywords: schizophrenia, iloperidone, antipsychotic

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]